ArticleFrontiers in pharmacology2026

Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event reporting system (FAERS).

Xihui Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.